Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1).

Daniele SantiniHaoran LiGiandomenico RovielloSe Hoon ParkEnrique GrandeJakub KucharzUmberto BassoOndrej FialaFernando Sabino Marques MonteiroAlexandr PoprachSebastiano ButiJavier Molina-CerrilloMartina CatalanoTomas BuchlerEmmanuel SerontJawaher AnsariZin W MyintMarwan GhosnFabio CalabròRay Manneh KoppDipen BhuvaMaria T BourlonMichela RobertoMattia Alberto Di CivitaVeronica MollicaAndrea MarchettiAndrey SoaresNicola BattelliMarco RicciRavindran KanesvaranAristotelis BamiasCamillo PortaFrancesco MassariMatteo Santoni

Published in: Targeted oncology (2024)

patients, emphasizing the challenges of this precociously resistant subgroup. Identified predictors could guide risk stratification, aiding clinicians in tailored therapeutic approaches.

Keyphrases

end stage renal disease
renal cell carcinoma
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
palliative care
clinical trial
study protocol